Dosing begins with a trial of a new immunotherapy for the treatment of advanced solid tumors

A phase 1a/1b, first-in-human study of a new immunotherapy agent, AB248, has given the agent to the first patient with a locally advanced or metastatic solid tumor. The first patient received a dose of a new therapy, AB248, as part of AB248-011 (NCT05653882) a phase 1a/1b study of immunotherapy in combination with pembrolizumab (Keytruda) for …

Dosing begins with a trial of a new immunotherapy for the treatment of advanced solid tumors Read More »